Your shopping cart is currently empty

SPEN-IN-1 (compound X1) is a selective inhibitor of the SPEN protein factor, with a dissociation constant (K d) of 47 nM. It specifically targets RepA, a 431-nucleotide domain within Xist (a non-coding RNA prototype), characterized by 8.5 repeats of a GC-rich motif instrumental in gene silencing [1].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $278 | 5 days | 5 days |
| Description | SPEN-IN-1 (compound X1) is a selective inhibitor of the SPEN protein factor, with a dissociation constant (K d) of 47 nM. It specifically targets RepA, a 431-nucleotide domain within Xist (a non-coding RNA prototype), characterized by 8.5 repeats of a GC-rich motif instrumental in gene silencing [1]. |
| In vitro | SPEN-IN-1 (0-100 μM) inhibits RepA-PRC2 and RepA-SPEN with IC50 values of 30 μM and 48 μM, respectively, and inhibits RepA, PRC2, and SPEN with Kd values of 400 nM, 47 nM, and 420 nM, respectively [1]. SPEN-IN-1 selectively disrupts the interaction between Xist and homologous proteins both in vitro and in cells and markedly suppresses the accumulation of H3K27me3 and PRC2 [1]. |
| In vivo | SPEN-IN-1 reduces the in vivo interaction of RepA-SPEN [1]. |
| Molecular Weight | 416.47 |
| Formula | C27H20N4O |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.